Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price: 7.25
Bid: 7.00
Ask: 7.50
Change: 0.00 (0.00%)
Spread: 0.50 (7.14%)
Open: 7.25
High: 7.25
Low: 7.25
Yest. Close: 7.25
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 14 August AvastHalf Year ResultsLookersHalf Year BeattyHalf Year Year

13 Aug 19 15:58

Scancell Progresses Trials In "Busy And Productive" Six Months

(Alliance News) - Scancell Holdings PLC said on Monday it has been a "busy and productive" six months for the company.The company said that active patient recruitment for the two

1 Jul 19 14:42

Scancell Appoints Vulpes Investment Management Co-Founder To Board

(Alliance News) - Scancell Holdings PLC on Tuesday said it has appointed Vulpes Investment Management Co-Founder & Portfolio Manager Martin Diggle to its board.Diggle joins the cancer a

18 Jun 19 14:40

Scancell Shares Jump 30% As Vulpes Invests GBP4 Million (ALLISS)

(Alliance News) - Scancell Holdings PLC's shares soared Thursday as it received GBP3.9 million from a new investor.Scancell shares were up 31% in afternoon trade at a price of 7.00 Life

13 Jun 19 13:48

N4 Pharma Appoints John Chiplin as Non-Executive Chairman

LONDON (Alliance News) - N4 Pharma PLC on Tuesday said it appointed John Chiplin as non-executive chair of the company with immediate effect.Furthermore, the pharmaceutical firm appointed a

21 May 19 13:25

Scancell partnership with Cancer Research moves closer to clinic

(Sharecast News) - Immunotherapy developer Scancell Holdings updated the market on its clinical development partnership with Cancer Research UK for the development of the ;ImmunoBody' vaccine, SCIB2, as a potential treatment for patients with solid tumours, including non-small cell lung cancer (NSCLC), on Monday.

20 May 19 11:03

Scancell Says Cancer Vaccine SCIB2 Will Be Given Using New Formulation

LONDON (Alliance News) - Scancell Holdings PLC said Monday cancer vaccine SCIB2 is to be administered using a new nanoparticle formulation in an early stage trial.Shares in Scancell were up

20 May 19 11:02

Scancell Creates Advisory Board And Prepares For Drug Trials

LONDON (Alliance News) - Scancell Holdings PLC on Friday said it has established a clinical advisory board and has begun manufacturing and toxicity testing on its tumour drug in immunotherapy were

10 May 19 10:49

Scancell gets go-ahead for UK second phase trials of 'SCIB1'

(Sharecast News) - Cancer immunotherapy developer Scancell Holdings has received all of the UK regulatory, ethical and legal approvals required to initiate the phase 2 clinical trial to assess the safety and efficacy of 'SCIB1' in metastatic melanoma patients also receiving the checkpoint inhibitor pembrolizumab (Keytruda), it announced on Thursday.

25 Apr 19 11:19

Scancell Holdings expands IP protection with Japanese patent

(Sharecast News) - Scancell Holdings on Monday won a Japanese patent for its Moditope immunotherapy platform, which stimulates the production of cells that overcome the immune suppression induced by tumours.

8 Apr 19 11:34

Scancell Gets Japan Patent Protecting Moditope Immunotherapy Platform

LONDON (Alliance News) - Scancell Holdings PLC on Monday said the Japanese Patent Office has granted a patent providing protection for its Moditope immunotherapy platform.The cancer said T

8 Apr 19 11:27

Scancell Holdings Gets Further Patent Protection In US And Europe

LONDON (Alliance News) - Immunotherapy firm Scancell Holdings PLC has received a new patent for its Modi-1 drug candidate in the US, it said on Wednesday.The patent, granted by the US in in

20 Mar 19 13:38

Loss Widens As Scancell Continues Moditope Cancer Vaccine Development

LONDON (Alliance News) - Scancell Holdings PLC on Thursday said its loss widened in the first half of its year on mounting administrative expenses as its development of Moditope in Scancell were a

31 Jan 19 13:59

Scancell shares slip as losses widen in first half

(Sharecast News) - Cancer immunotherapies developer Scancell Holdings issued its interim results for the six months ended 31 October on Thursday, reporting a loss of £3.24m, widening from £2.02m year-on-year.

31 Jan 19 09:48

Scancell loses out on Cancer Research UK grant

(Sharecast News) - Immunotherapies developer Scancell has seen Cancer Research UK pass on its submission into the Grand Challenge research initiative.

23 Jan 19 11:20

Login to your account

Don't have an account? Click here to register.